Brukinsa bags broadest BTK label after FDA clears follicular lymphoma combo

07 Mar 2024
firstwordpharma.com
Clinical ResultDrug ApprovalPhase 3Phase 2Accelerated Approval
BeiGene notched its fifth US approval for Brukinsa (zanubrutinib) on Thursday when it became the first BTK inhibitor cleared to treat follicular lymphoma (FL). According to the drugmaker, Brukinsa now has the broadest label of all drugs in the class.
The FDA granted accelerated approval to Brukinsa in combination with Roche’s anti-CD20 antibody Gazyva (obinutuzumab) to treat relapsed or refractory FL patients after they’ve received two or more lines of systemic therapy. The combination received EU approval in November.
Thursday’s greenlight comes a little over a year after its most recent US approval, which was for relapsed/refractory chronic lymphocytic leukaemia. Brukinsa is also approved in both the US and Europe to treat mantle cell lymphoma, Waldenström's macroglobulinaemia and marginal zone lymphoma. For more, see ViewPoints: Safety makes Brukinsa first choice in chronic lymphocytic leukaemia.
The latest approval was based on the 217-patient Phase II ROSEWOOD study, in which Brukinsa plus Gazyva led to an overall response rate of 69% versus 46% for Gazyva alone. The combination also saw an 18-month duration of response of 69%.
Full approval in FL may depend on the results of the confirmatory Phase III MAHOGANY trial, which is comparing the Brukinsa/Gazyva combo against Revlimid (lenalidomide) plus Rituxan (rituximab).
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.